Related Experiment Video
Updated: May 17, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
The need for a systematic approach to statin switching: an analysis of real-world experience
Peter W Kakavas1, Judy Ly McManus, Thomas A Wolfe
1Peter W. Kakavas, MDDirector of the Echocardiographic and Vascular Laboratories and Cholesterol Modification Program, Heart Care Centers of Illinois, Mokena, and Assistant Professor of Medicine, Rush Medical Center, Chicago. Judy Ly McManus, PharmD Department of Medical Affairs, Medical Outcomes Specialists, Pfizer, Inc, New York. Thomas A. Wolfe, PharmD Department of Medical Affairs, Medical Outcomes Specialists, Pfizer, Inc, New York. Thomas Guidry, PharmD Department of Medical Affairs, Medical Outcomes Specialists, Pfizer, Inc, New York. Daniel N. Flores, PharmD Department of Medical Affairs, Medical Outcomes Specialists, Pfizer, Inc, New York. Linh B. ter Riet, PharmD Department of Medical Affairs, Medical Outcomes Specialists, Pfizer, Inc, New York. Jon J. Glover, PharmD Department of Medical Affairs, Medical Outcomes Specialists, Pfizer, Inc, New York. Heather Sell, PharmD Department of Medical Affairs, Medical Outcomes Specialists, Pfizer, Inc, New York.
Background:
In the advent of generic statins becoming increasingly available and with the recent addition of atorvastatin to the generic market, healthcare providers are often encouraged by payers to switch from a branded statin to an alternate, less costly agent.
Objective:
The aim of this study was to determine the impact of a therapeutic switch on cholesterol goal attainment among patients with existing cardiovascular disease (CVD) or risk factors for CVD.
Study Design:
A cross-sectional, multisite retrospective review of patient records evaluating low-density lipoprotein cholesterol (LDL-C) control before and after switching statins was conducted.
Methods:
Participants were 18 to 89 years olds who were stable on statin therapy and had 1 or more risk factors for CVD. Patients meeting switch criteria (n = 833) were evaluated for changes in their statin therapy and LDL-C goal attainment. Drug/dose information, cholesterol values, and goal attainment in accordance with National Cholesterol Education Panel Third Adult Treatment Panel guidelines were determined before and after the switch. Dose potency was based on mean LDL-C reductions.
Results:
Data were collected from 22 US sites. Risk factors for CVD were common, with 88.5% of patients identified as high risk. Overall, patients' mean LDL-C levels improved from 87.1 to 81.5 mg/dL, and goal attainment increased from 75.5% to 82.5% (P < .05). Switches to a comparable or higher statin/dose improved mean LDL-C and goal attainment (P < .05). However, in patients transitioned to a lower statin/dose equivalency (36.4%), mean LDL-C level increased from 79.8 to 85.6 mg/dL and goal attainment fell from 84.2% to 78.6% (P < .05). Logistic regression confirmed that LDL-C goal attainment was reduced by 53% in patients switched to a lower statin/dose (odds ratio, 0.47; 95% confidence interval, 0.30-0.76; P = .002) compared with patients switched to an equipotent dose. The use of adjunctive lipid-lowering therapies increased in patients switched to a lower statin/dose (P < .05).
Conclusions:
Cholesterol values and goal attainment can be negatively impacted when a systematic approach is not used and patients are switched to lower potency therapies.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Dosage Regimen: Individualization
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...